

Kyphoplasty and Vertebroplasty

Dates Reviewed: 10/2004, 10/2005, 11/2006, 11/2007, 11/2008, 07/2010, 06/2012, 04/2013, 04/2014,

04/2015, 12/2015, 02/2019, 02/2020

Developed By: Medical Necessity Criteria Committee

I. Description

Percutaneous vertebroplasty is a therapeutic, interventional radiologic procedure performed under imaging guidance that consists of the injection of medical grade cement through a needle into a painful fractured cervical, thoracic or lumbar vertebral body to stabilize the fracture. Vertebroplasty is performed in an attempt to relieve pain and strengthen the spine.

Percutaneous kyphoplasty is similar to vertebroplasty in that stabilization of a collapsed vertebra is accomplished by the injection of bone cement. Under fluoroscopic guidance, an inflatable balloon is inserted to expand a collapsed vertebral body to its natural height prior to the injection of the cement. With kyphoplasty, some of the bony deformity and resulting kyphosis may be reduced which will often significantly improve a patient's pain.

II. Criteria: CWQI HCS-0049A

- A. For the following urgent/emergent indications/conditions, vertebroplasty or kyphoplasty will be covered to plan limitations WITHOUT a trial of conservative treatment and WITHOUT submission of imaging:
 - a. Primary metastatic neoplastic disease causing pathological fracture
 - b. Documentation of severe debilitating pain and/or dysfunction to the point of being incapacitated
- B. For non-urgent/non-emergent indications/conditions, Vertebroplasty or kyphoplasty will be covered to plan limitations when ALL of the following have been met:
 - a. Patients with acute (< 4 months of symptoms) vertebral collapse and persistent, debilitating pain in the cervical, thoracic or lumbar bodies confirmed by plain film, CT or by MRI resulting from **1 or more** of the following:
 - i. Painful osteoporotic or osteolytic vertebral collapse/compression fractures (e.g. Kummell's disease)
 - ii. Osteolytic metastases including destruction of a vertebral body by multiple myeloma
 - iii. Painful and aggressive space occupying lesions of a vertebral body (hemangioma/eosinophilic granuloma)
 - iv. Primary malignant neoplasm of bone or bone marrow
 - v. Pre-surgical stabilization of a vertebral body to facilitate a fusion operation

- vi. Steroid induced fractures
- vii. Secondary osteolytic metastasis, excluding sacrum and coccyx
- b. Persistent debilitating pain including both of the following:
 - Pain level at least 7 on Visual Analog Scale (VAS/Number Rating Scale (NRS) on a daily basis
 - ii. Clinically significant functional impairment (e.g. inability to perform basic activities of daily living [ADLs], such as ambulation, sitting, bathing, transfers).
- c. Either of the following:
 - Acute (0-6 weeks) axial back pain that persists at a level which prevents independent transfers and/or ambulation and correlates with the level of the fracture
 - ii. Subacute (more than 6 weeks) axial pain in the thoracic/lumbar spine
 - 1. Failure of clinically significant improvement after at least 4 weeks of BOTH of the following (unless contraindicated):
 - a. Prescription strength analgesics, steroids, and/or NSAIDS
 - b. Physical therapy or chiropractic therapy
- C. Moda Health considers Vertebral Augmentation (Percutaneous Vertebroplasty/Kyphoplasty) NOT medically necessary for ANY of the following:
 - a. The presence of any of the following contraindications:
 - i. Uncorrected coagulation disorders or anticoagulation therapy
 - ii. Active osteomyelitis of the affected vertebra
 - iii. Neurological symptoms related to spinal decompression
 - iv. Lack of neurological backup for emergency decompression in the event a neurological deficit develops during the injections of PMMA
 - v. Absence of a confirmed acute or subacute fracture
 - vi. Unstable fracture or requirement for stabilization procedure in the same or adjacent spinal region
 - vii. Asymptomatic vertebral compression fracture
 - viii. Burst fracture with retropulsed fragments
 - ix. Known allergy to materials used in either procedure
 - x. Myelopathy associated with a bone fragment in the spinal canal or cord compression from a tumor
 - xi. Extensive vertebral destruction
 - xii. Potential space occupying lesions causing cord compression (tumor, bone fragment)
 - xiii. Collapse of vertebral body to less than the level of the vertebra plana
 - xiv. The use of Norian XR cement and Norian SRS cement products is prohibited because they are not FDA approved
 - xv. Radiculopathy from a herniated intervertebral disc
 - xvi. Untreated symptomatic foraminal or canal stenosis, facet arthropathy, or other significant coexistent spinal or bony pain generators
 - xvii. Septicemia and any active infection (including UTI)
 - xviii. Presence of painful metastases to areas other than the spine, spinal cord compression, primary bone and osteoblastic tumors, solitary plasmacytomas
 - xix. Severe cardiopulmonary disease
 - xx. Applications in the cervical spine

- b. The presence of ANY of the following alternative causes of axial back pain:
 - i. Lumbar/thoracic radiculopathy or facet disease
 - ii. Lumbar/thoracic/sacral trigger points
 - iii. Sacral insufficiency fractures
- D. Moda Health considers Vertebral Augmentation (Percutaneous Vertebroplasty/Kyphoplasty) experimental or investigational for EITHER of the following:
 - a. Percutaneous vertebral augmentation for ANY of the following:
 - i. Non-painful/non-aggressive vertebral hemangioma
 - ii. Vertebrae of the cervical spine and thoracic levels T1-T4
 - iii. Stabilization of insufficiency fractures or lesions of the sacrum (sacroplasty) or coccyx (coccygeoplasty)
 - iv. Prophylactic treatment for osteoporosis of the spine
 - v. Prophylactic treatment for chronic back pain of longstanding duration (> 6 months), even if associated with an old compression fracture(s)
 - vi. Percutaneous mechanical vertebral augmentation using any device other than a balloon device, including, but not limited to: use of the Kiva system and radiofrequency-assisted vertebral augmentation
 - b. Spinoplasty (e.g. OptiMesh® 1500E Polyethylene Terephthalate [PET] mesh pouch)

III. Information Submitted with the Prior Authorization Request:

- 1. Medical records from the treating physician documenting the spinal level involved, the severity of pain, previous treatments tried, and the patient's neurologic condition
- 2. X-Ray, CT, or MRI report documenting vertebral collapse

IV. Applicable CPT or HCPC codes covered:

Codes	Description
22510	Percutaneous vertebroplasty, 1 vertebral body, unilateral or bilateral injection; thoracic
22511	Percutaneous vertebroplasty, 1 vertebral body, unilateral or bilateral injection; lumbar
22512	Percutaneous vertebroplasty, 1 vertebral body, unilateral or bilateral injection; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)
22513	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (e.g., kyphoplasty), including of all imaging guidance; thoracic
22514	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty), including all imaging guidance; lumbar
22515	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty); each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)

V. Annual Review History

Review Date	Revisions	Effective Date
04/2013	Annual Review: Added table with review date, revisions, and effective	04/24/2013
	date	
04/2014	Annual Review: No change	04/30/2014
04/2015	Annual Review: No change	04/25/2015
07/2015	Added ICD-9 and ICD-10 Codes	07/2015
12/1/15	Edited with new LCD- Deleted ICD-9 codes	12/2/2015
03/2017	Annual Review: Updated to new template	03/22/2017
02/27/2019	Annual Review: Updated reference to Medicare resource; Updated to	03/01/2019
	include more specific criteria	
02/26/20	Annual Review: removed deleted codes, no content change	03/01/2020

VI. References

- 1. Babb A, Carlson WO. Vertebral compression fractures: treatment and evaluation. S D Med. 2006 Aug;59(8):343-5, 347.
- 2. Balloons for bones. Supplied by the office of Dr. Andrew J. Kokkino
- 3. Bono CM, Heggeness M, Mick C, et al.; North American Spine Society. Newly released vertebroplasty randomized controlled trials: A tale of two trials. Spine J. 2009 Oct 10. [Epub ahead of print]
- 4. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, et al. randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009 Aug 6;361(6):557-68.
- 5. Burton AW, Mendel E. Vertebroplasty and kyphoplasty. Pain Physicians. 2003 Jul;6(3):335-41.
- 6. Ledlie JT, Renfro, M (2003). Ballooon kyphoplasty: one-year outcomes in vertebral body height restoration, chronic pain, and activity levels. J. Neurosurgery: Spine. Jan. 2003; 98: 36-42.
- 7. Deen HG. Current status of percutaneous vertebral augmentation techniques for vertebral compression fractures. Neurol Neurochir Pol. 2006 July-August; 40(4):320-326.
- 8. Eck JC, Nachtigall D, Humphreys SC, Hodges SD. Comparison of vertebroplasty and balloon kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature. Spine J. 2008 May-Jun;8(3):488-97. Epub 2007 May 29.
- 9. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful
- 10. Garfin SR, Buckley RA, Ledlie J, et al. Balloon kyphoplasty for symptomatic vertebral body compression fractures results in rapid, significant, and sustained improvements in back pain, function, and quality of life for elderly patients. Spine 2006 Sep 1;31(19):2213-20.
- 11. Hiwatashi A, Sidhu R, Lee R, et al. Kyphoplasty versus vertebroplasty to increase vertebral body height: a cadaveric study. Radiology. 2005 Dec; 237:1115-1119.
- 12. Hulme PA, Krebs J, Ferguson SJ, et al. Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies. Spine. 2006 Aug 1;31(17):1983-2001.
- 13. Jensen ME, McGraw Jk, Cardella Jf, Hirsch JA. Position statement on percutaneous vertebral augmentation: a consensus statement developed by the American Society of Interventional and

- Therapeutic Neuroradiology, Society of Interventional Radiology, American Association of Neurological Surgeons/Congress of Neurological Surgeons, and American Society of Spine Radiology. Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S326-31.
- 14. Karliner L. Balloon kyphoplasty as a treatment for vertebral compression fractures. Technology Assessment. San Francisco, CA: California Technology Assessment Forum (CTAF); June 17, 2009.
- 15. Kasperk C, Grafe IA, Schmitt S, Nöldge G, Weiss C, Da Fonseca K, et al. Three-year outcomes after kyphoplasty in patients with osteoporosis with painful vertebral fractures. J Vasc Interv Radiol. 2010 May;21(5):701-9. Epub 2010 Mar 20.
- 16. Klazen CA, Lohle PN, de Vries J, Jansen FH, Tielbeek AV, Blonk MC, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet. 2010 Sep 25;376(9746):1085-92. Epub 2010 Aug 9
- 17. National Institute for Clinical Excellence (NICE). Balloon kyphoplasty for vertebral compression fractures. Interventional procedure guidance 166. London, UK: NICE; 2006 Apr. Revised 2008 Jan. Accessed Mar 9 2010. Available at URL address: http://www.nice.org.uk/Guidance/IPG166/Guidance/pdf/English
- 18. National Institute for Clinical Excellence (NICE). Percutaneous vertebroplasty. Interventional procedure guidance 12. London, UK: NICE; 2003 Nov. Accessed Mar 9 2010. Available at URL address: http://www.nice.org.uk/page.aspx?o=85733
- 19. Rousing R, Andersen MO, Jespersen SM, et al. Percutaneous vertebroplasty compared to conservative treatment in patients with painful acute or subacute osteoporotic vertebral fractures: Three-months follow-up in a clinical randomized study. Spine. 2009;34(13):1349-1354.
- 20. Society of Interventional Radiology (SIR). Society of Interventional Radiology commentary on vertebroplasty and the August studies in the New England Journal of Medicine. SIR Commentary. Fairfax, VA: SIR; November 24, 2009.
- 21. U.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH). Complications related to the use of bone cement and bone void fillers in treating compression fractures of the spine. FDA Public Health Web Notification. Rockville, MD: FDA; updated May 7, 2004. Assessed on July 21, 2011 at: http://www.fda.gov/cdrh/safety/bonecement.html. Centers for Medicare and Medicaid Services (CMS). Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis and malignancy. Draft Technology Assessment. Medicare Coverage Database. Baltimore, MD: CMS; 2005. Assessed July 21, 2011 at: http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=25.
- 22. Vertebral body fractures in cancer patients. J. Neurosurgery: Spine. Jan. 2003; 98: 21-30.
- 23. Vertebroplasty benefits selected patients. Hayes Alert; Feb. 2003; VI(2).
- 24. Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009 Mar 21;373(9668):1016-24. Epub 2009 Feb 24.
- 25. Centers for Medicare & Medicaid Services; Local Coverage Determination (LCD): Percutaneous Vertebral Augmentation (L34106); Noridian Healthcare Solutions; Revision Date 10/1/2015; Effective date 10/01/2015
- 26. Physician Advisors

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description	
M48.50XA	Collapsed vertebra, not elsewhere classified, site unspecified, initial encounter for	
	fracture	
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial	
	encounter for fracture	
M81.0	Age-related osteoporosis without current pathological fracture	
M81.0	Age-related osteoporosis without current pathological fracture	
M81.8	Other osteoporosis without current pathological fracture	
M84.48XA	Pathological fracture, other site, initial encounter for fracture	
M84.68XA	Pathological fracture in other disease, other site, initial encounter for fracture	
M89.00	Algoneurodystrophy, unspecified site	
S12.200A	Unspecified displaced fracture of third cervical vertebra, initial encounter for closed	
	fracture	
S12.201A	Unspecified nondisplaced fracture of third cervical vertebra, initial encounter for closed	
	fracture	
S12.300A	Unspecified displaced fracture of fourth cervical vertebra, initial encounter for closed	
	fracture	
S12.301A	Unspecified nondisplaced fracture of fourth cervical vertebra, initial encounter for	
	closed fracture	
S12.400A	Unspecified displaced fracture of fifth cervical vertebra, initial encounter for closed	
	fracture	
S12.401A	Unspecified nondisplaced fracture of fifth cervical vertebra, initial encounter for closed	
	fracture	
S12.500A	Unspecified displaced fracture of sixth cervical vertebra, initial encounter for closed	
	fracture	
S12.501A	Unspecified nondisplaced fracture of sixth cervical vertebra, initial encounter for closed	
	fracture	

ICD-10	ICD-10 Description
S12.600A	Unspecified displaced fracture of seventh cervical vertebra, initial encounter for closed fracture
S12.601A	Unspecified nondisplaced fracture of seventh cervical vertebra, initial encounter for closed fracture
S12.9XXA	Fracture of neck, unspecified, initial encounter
S22.009A	Unspecified fracture of unspecified thoracic vertebra, initial encounter for closed fracture
S32.009A	Unspecified fracture of unspecified lumbar vertebra, initial encounter for closed fracture
S32.10XA	Unspecified fracture of sacrum, initial encounter for closed fracture
SS32.2XXA	Fracture of coccyx, initial encounter for closed fracture

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

Jurisdiction(s): J	NCD/LCD Document (s): L34106	
Noridian Local Coverage Determination (LCD) Percutaneous Vertebral Augmentation (L34106)		

NCD/LCD Document (s):

https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=34106&ver=27&Date=&DocID=L34106&SearchType=Advanced&bc=KAAAABAAAAA&

Medicare Part B Administrative Contractor (MAC) Jurisdictions					
Jurisdiction	Applicable State/US Territory	Contractor			
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC			